Acyclovir

C. diff Risk

NA

Oral Bioavailability

NA

Approximate Cost

NA

Spectrum Of Activity

Dosing

< 32 weeks GA

  • 40 mg/kg/day IV divided Q12H

> 32 weeks GA

  • 60 mg/kg/day IV divided Q8H

General Information

Drug Monitoring

CBC and renal function recommended

First Line Indications

Empiric and targeted therapy for Herpes simplex and varicella zoster virus infections